These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 3099393

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S, Yeap B, Vogl S, Carbone P.
    Cancer; 1996 Feb 15; 77(4):733-42. PubMed ID: 8616766
    [Abstract] [Full Text] [Related]

  • 3. The use of high-dose megestrol acetate in the treatment of ovarian adenocarcinoma.
    Geisler HE.
    Semin Oncol; 1985 Mar 15; 12(1 Suppl 1):20-2. PubMed ID: 3975647
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R, Hornedo J, Colomer R, Mendiola C, Brandariz A, Sevilla E, Alvarez-Vicent J, Cortés-Funes H.
    Semin Oncol; 1995 Dec 15; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T, Vance R, Puneky L, Khansur T.
    Gynecol Oncol; 1994 Dec 15; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [Abstract] [Full Text] [Related]

  • 10. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Covens A, Blessing J, Bender D, Mannel R, Morgan M, Gynecologic Oncology Group.
    Gynecol Oncol; 2006 Mar 15; 100(3):586-90. PubMed ID: 16249022
    [Abstract] [Full Text] [Related]

  • 11. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M, Alberts DS, Garcia DJ, Emerson J, Fanta P, Liu R, Salmon SE.
    Gynecol Oncol; 1994 Dec 15; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [Abstract] [Full Text] [Related]

  • 12. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
    Niijima T, Aso Y, Akaza H, Fujita K, Fuse H, Hosaka M, Isurugi K, Kamidono S, Katayama T, Kawabe K.
    Hinyokika Kiyo; 1990 Nov 15; 36(11):1343-60. PubMed ID: 2126912
    [Abstract] [Full Text] [Related]

  • 13. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T, Becker A, Pigorsch S, Pelz T, Bloching M, Passmann M, Lotterer E, Hänsgen G, Dunst J.
    Strahlenther Onkol; 2003 Oct 15; 179(10):673-81. PubMed ID: 14566475
    [Abstract] [Full Text] [Related]

  • 14. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group.
    Emons G, Ortmann O, Teichert HM, Fassl H, Löhrs U, Kullander S, Kauppila A, Ayalon D, Schally A, Oberheuser F.
    Cancer; 1996 Oct 01; 78(7):1452-60. PubMed ID: 8839551
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E, Guastalla JP, Weber B, Curé H, Orfeuvre H, Mousseau M, Vincent P, Diéras V, Tubiana-Mathieu N, Jacquin JP, Mignot L, Leduc B, Paraïso D, Viens P.
    Semin Oncol; 1997 Oct 01; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Megestrol acetate for the palliation of advanced ovarian carcinoma.
    Geisler HE.
    Obstet Gynecol; 1983 Jan 01; 61(1):95-8. PubMed ID: 6185891
    [Abstract] [Full Text] [Related]

  • 19. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
    Gershenson DM, Morris M, Burke TW, Levenback C, Wolf J, Lee JJ, Thall PF, Atkinson EN, Silva EG, Wharton JT.
    Cancer; 1999 Dec 01; 86(11):2291-300. PubMed ID: 10590370
    [Abstract] [Full Text] [Related]

  • 20. Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study.
    Berek JS, Markman M, Stonebraker B, Lentz SS, Adelson MD, DeGeest K, Moore D.
    Gynecol Oncol; 1999 Oct 01; 75(1):10-4. PubMed ID: 10502418
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.